The current status of combined modality treatment containing chemotherapy in patients with esophageal cancer

1990 ◽  
Vol 19 (3) ◽  
pp. 813-815 ◽  
Author(s):  
Muhy Al-Sarraf
2020 ◽  
Vol 66 (3) ◽  
pp. 283-290
Author(s):  
Aleksey Dobrodeev ◽  
Sergey Afanasev ◽  
Umidzhon Urmonov ◽  
Aleksandra Avgustinovich ◽  
Irina Frolova ◽  
...  

The purpose of the study: to analyze the efficacy of combined modality treatment including preoperative chemotherapy with gemcitabine/cisplatin in patients with stage II-III esophageal cancer (EC). Materials and methods: The study included 70 patients with stage II-III EC, who were treated at the Cancer Research Institute (Tomsk, Russia) from 2012 to 2019. The patients were divided into 2 groups. Group I comprised 35 patients, who received 2 cycles of preoperative chemotherapy with gem-citabine (1250 mg/m2 on days 1 and 8) and cisplatin (80 mg/ m2 on day 1) followed by radical surgery. Group II included 35 patients who underwent surgery alone. All patients underwent subtotal resection of the esophagus with simultaneous esophageal reconstruction using gastric tube (68.6%) or colon tissue (31.4%). Results: The overall tumor response to preoperative chemotherapy according to RECIST 1.1 criteria was 57.1%, including complete response (5.7%) and partial response (51.4%). No severe complications were observed. R0 resection was achieved in all patients (100%). No difference in the rate of postoperative complications between Group I and Group II was found (34.3% and 40%, respectively). There was no statistically significant difference in the mortality rate between treatment groups (8.6% versus 57%) (p>0.05). Pathological complete tumor response was 5.7%. In Group I patients, the 2-year disease-free and overall survival rates were 71.8% and 81.3%, respectively. The corresponding values in Group II patients were 39.4% and 51.5%, respectively (p=0.01). Conclusion: Preoperative chemotherapy for patients with stage II-III EC demonstrated high response rates, having no adverse effect on the perioperative period and mortality. The 2-year survival rates were significantly higher in patients, who received combined modality treatment with preoperative chemotherapy than in patients, who underwent surgery alone.


2005 ◽  
Vol 44 (2) ◽  
pp. 168-173 ◽  
Author(s):  
Dirk Neuhof ◽  
Florian Neumayer ◽  
Wolfgang Einbeck ◽  
Kai Haschemian ◽  
Sabine K. Mai ◽  
...  

Author(s):  
U. B. Urmonov ◽  
A. Yu. Dobrodeev ◽  
S. G. Afanasyev ◽  
A. V. Avgustinovich ◽  
M. Yu. Volkov ◽  
...  

2016 ◽  
Vol 88 (5) ◽  
Author(s):  
Kamil Pudło ◽  
Alan Błotniak ◽  
Tomasz Skoczylas ◽  
Andrzej Dąbrowski ◽  
Andrzej Szawłowski ◽  
...  

AbstractAmong many various factors affecting the outcome of cancer treatment one can distinguish patient, tumor- and treatment-related factors. The association of patient-related factors and results of a combined modality therapy of esophageal cancer has not been extensively explored.was to analyze the impact of patient-related constitutional and environmental factors on early results of combined modality therapy of esophageal squamous cell carcinoma.We retrospectively analyzed prospectively collected data of 84 patients with esophageal cancer randomly assigned to a combined modality treatment. We evaluated the relationship between early outcome of neoadjuvant therapy (overall toxic events, serious toxic events, treatment-related mortality, clinical and pathological response to the treatment) or surgical treatment (postoperative morbidity, mortality and curative resections – R0) and constitutional (age, gender, height, body mass index, Karnofski Performance Status – KPS, blood type) or environmental (inhabitation, smoking duration and intensity, frequency and amount of alcohol consumption and occupational exposure) patient-related factors.Significantly more neoadjuvant therapy related deaths were found in patients with KPS 70-80 (p=0.0016). Interestingly, significantly more toxic events (p=0.0034) after neoadjuvant therapy and a higher postoperative morbidity rate (p=0.0293) were observed in nonsmokers. Similarly, significantly more toxic events (p=0.0029) after neoadjuvant therapy and a higher postoperative mortality rate (p=0.0405) were found in light drinkers.Smoking and consumption of excessive amount of alcohol may attenuate toxic effect of neoadiuvant and surgical therapy in patients treated due to esophageal cancer. The information regarding the mentioned above addictions should not result in giving up an attempt to provide a curative treatment.


1998 ◽  
Vol 84 (2) ◽  
pp. 252-258 ◽  
Author(s):  
Michele Tordiglione ◽  
Maurizio Kalli ◽  
Vittorio Vavassori ◽  
Roberto Luraghi

We have performed a review of recent literature about combined modality therapy in esophageal cancer. Radiobiological principles and radio-chemotherapy interactions modalities in clinical experiences have been considered. Therapeutic schedules, modalities of implementation, and the most relevant clinical results obtained by the major clinical research groups have been emphasized. We also comment on the current role of surgery and on the clinical questions arising in combined radio-chemotherapy treatment.


Sign in / Sign up

Export Citation Format

Share Document